| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2015: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2014: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2013: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
|
|---|
| Outline of Final Research Achievements |
In this project, we evaluated that CL/P patient-derived SHED expressed an enhanced phosphorylation of ERK1/2 to suppress their regenerative capacity to form bone tissue. The enhancement of ERK1/2 in CL/P patient-derived SHED was caused by hypomethylation of DUSP4 and 6 DNA promoters. The inhibited bone regenerative capacity in CL/P patient-derived SHED was rescued by inhibition of ERK1/2 phosphorylation. These findings suggested that, in future, a promising therapeutics with autologous SHED-based bone regeneration will be developed in CL/P treatment.
|
